Search
Sumario de resultados
TIpos de contenido
Fecha
-
NewClimate Pact Ambassadors: “We have to go from being aware to using good judgement as a soc...
For World Environmental Education Day, we spoke with four of the 70 Spanish ambassadors working to raise awareness, particularly among the younger generation, about climate change and its consequences
-
New54% of Europeans consider their current physical health to be good or very good, as survey...
“Merck Survey: Europeans' perception of health two years after the start of Covid 19” carried out in 10 countries across Europe Almost a quarter of Europeans say they have reduced their alcohol and
-
-
-
OfferPROJECT LAB MANAGER
-
-
OfferRESEARCH SCIENTIST
-
NewNeurofix opens final funding round before availability of phase IIa results for its clinic...
Increase in capital is set to 3.5 million euros with a discount of 10% on a valuation of 20 million euros. It coincides with the end of recruitment for the clinical trials for its drug to treat
-
NewFinal stretch in phase IIa of clinical trial for ground-breaking Spanish drug indicated to...
In three months, biotechnology company Neurofix will have the first results of phase IIa of NFX88 and will be able to begin phase IIb/III towards the end of the year
-
NewAlmirall initiates experimental phase of Lebrikizumab trial in AD patients that have faile...
The ADvantage study, whose principal investigator and coordinator is Professor Richard Warren of the University of Manchester, began in July 2021 after being submitted to the ethics committees of 80
-
NewAbility Pharmaceuticals continues with the clinical development for ABTL0812 as a first li...
ABTL0812 is administered in combination with FOLFIRINOX in a double blind, randomized and placebo controlled clinical trial The University of Cincinnati Medical Center (Cincinnati, OH, EEUU) and the
-
NewDIVERSA plans to attend SLAS2022 in Boston (February 5-9th, 2022)
DIVERSA is an early-stage biotech and drug delivery company founded in 2022 in Santiago de Compostela (Spain) and offers a novel patented nanotechnology based on non-toxic, biodegradable lipids.
-
NewPeptomyc opens a 25 million round of investment and secures 8.6 million euros from its cur...
The spin-off from VHIO (Vall d'Hebron Institute of Oncology) and ICREA – Peptomyc – has developed the first oncological treatment based on MYC inhibition,
-
NewA new in silico platform that facilitates the evaluation of mutagenicity with regulatory v...
Mutagenicity (capacity to alter cellular genetic material) is one of the most important parameters for evaluating the possible toxicity of chemical products, particularly during their mandatory
-
NewIntegra Therapeutics secures €4.5-million in funding from AdBio Partners, Invivo Capital ...
Integra is a biotechnology company that is creating next-generation gene writing tools to boost the efficiency and safety of advanced therapies
-
NewAgomab Therapeutics to Acquire Origo Biopharma
The acquisition strengthens Agomab as a leader in targeting growth factor pathways Origo Biopharma is a Spanish biotech founded in Galicia by Julio Castro and GalChimia, and led by Ramon Bosser Asabys
-
NewNew generation of digitised biosensors for cutting-edge food analytical monitoring
The food industry is no stranger to changes and adapts in order to maintain its competitiveness and quality, both locally and internationally
-
NewBayer and Mammoth Biosciences to collaborate on novel gene editing technology
Agreement strengthens Bayer’s new cell and gene therapy platform further / Supports Mammoth’s vision of unlocking the full potential of novel CRISPR systems / Mammoth to receive upfront payment of USD
-
Press releaseNote from AseBio on recent regulation actions affecting the sale of diagnostics test kits ...
AseBio regrets the fact that Spanish manufacturers of SARS-CoV-2 antigen detection tests have not been at any point considered as an essential component of the solution to the pandemic
-
NewNote from AseBio on recent regulation actions affecting the sale of diagnostics test kits ...
AseBio regrets the fact that Spanish manufacturers of SARS-CoV-2 antigen detection tests have not been at any point considered as an essential component of the solution to the pandemic
-